Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Agilent Alliance to Remain Intact After Merck Acquisition

NEW YORK, May 16 – Merck’s acquisition of Rosetta Inpharmatics will not affect the alliance between Rosetta and Agilent Technologies, an exclusive distributor of the Rosetta Resolver gene expression system, Merck and Agilent said Wednesday.

Following Merck’s acquisition of Rosetta, Agilent will continue to work with Rosetta as the only outside distributor of Rosetta Resolver, and will continue to work with Rosetta to develop gene expression technologies.

"Merck is enthusiastic about the tools developed by Rosetta and our interaction with Agilent," Bennett Shapiro, executive vice president of worldwide licensing and external research at Merck Research Laboratories, said in a statement.

"Our company will continue the activities related to the Rosetta Resolver business and the key inkjet array technology. Moreover, we look forward to obtaining DNA microarrays from Agilent and utilizing such technologies for drug discovery."

Rosetta is a major purchaser of Agilent DNA microarrays.

Following completion of the acquisition, Rosetta will be run as a wholly owned Merck subsidiary and will continue to operate under the name Rosetta Inpharmatics.

Separately, Agilent also announced that it was launching a human cDNA microarray kit, which contains Incyte’s Human UniGene 1 and Human Drug Target clone sets. Agilent said the new product would be the first in a number of microarray products the company would launch this year.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.